<?xml version="1.0" encoding="UTF-8"?>
<ref id="B122">
 <label>122.</label>
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name name-style="western">
    <surname>Barve</surname>
    <given-names>M</given-names>
   </name>
   <span xml:space="preserve" class="x" xmlns="http://www.w3.org/1999/xhtml">, </span>
   <name name-style="western">
    <surname>Kuhn</surname>
    <given-names>J</given-names>
   </name>
   <span xml:space="preserve" class="x" xmlns="http://www.w3.org/1999/xhtml">, </span>
   <name name-style="western">
    <surname>Lamont</surname>
    <given-names>J</given-names>
   </name>
  </person-group>
  <etal/>
  <article-title>Follow-up of bi-shRNA furin/GM-CSF engineered autologous tumor cell (EATC) immunotherapy Vigil
   <sup>®</sup> in patients with advanced melanoma
  </article-title>. 
  <source>Biomed. Genet. Genomics</source>
  <volume>1</volume>(
  <issue>3</issue>), 
  <fpage>81</fpage>–
  <lpage>86</lpage> (
  <year>2016</year>).
 </mixed-citation>
</ref>
